Company intelligence / Profile preview
Huons
- Ownership
- Public · 243070
- Employees
- ~900
- Development stage
- Other
Overview
Huons has a strong commercial presence in Korea and internationally with injectable drugs (notably local anesthetics), eye drops including preservative-free formulations with leading market share in Korea ("Kynex"), medical devices, dietary supplements/probiotics. Recent clinical progress includes Phase I IND approval for HUC1‑394 targeting dry eye disease. The company continues to expand its biopharmaceutical pipeline through acquisitions like PanGen to develop biosimilars/human-derived enzymes such as hyaluronidase.
- Therapeutic areas
- OphthalmologyNeurologyWomen's Health
- Modalities
- Small moleculesbiologicshyaluronic acid productshuman-derived enzymes such as hyaluronidase
- Industry
- Biotech
Drug pipeline
16 assets15 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $137.4M
- Total revenue
- $455.2M
- Enterprise value
- $211.6M
Beyond the preview
Go deeper on Huons.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Huons.